Azathioprine in inflammatory bowel disease, a safe alternative?

被引：20
|
作者：
Tanis, AA [1 ]
机构：
[1] Erasmus Univ, Hosp Dijkzigt, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands
来源：
MEDIATORS OF INFLAMMATION | 1998年 / 7卷 / 03期
关键词：
azathioprine; 6-mercaptopurine; inflammatory bowel disease; bone marrow suppression; side effects; pregnancy;
D O I：
10.1080/09629359891045
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
AZATHIOPRINE and its metabolite 6-mercaptopurine are effective in the treatment of inflammatory bowel disease. They are mostly used for reduction of the use of steroids, maintenance therapy after remission induction by cyclosporin and treatment of fistulae in Crohn's disease. Adverse effects occur in about 15% of patients. The main side effects are pancreatitis, allergic reactions, fever and bone marrow suppression. Symptoms, management and prevention are discussed. A blood monitoring schedule is suggested. Azathioprine and 6-mercaptopurine seem to be safe in pregnancy. There may be a slight increased risk for developing a non-Hodgkin's lymphoma.
引用
收藏
页码：141 / 144
页数：4
相关论文
共 50 条
  • [1] 6-Mercaptopurine as a Safe Therapeutic Alternative for Patients with Inflammatory Bowel Disease Intolerant to Azathioprine
    Ott, Claudia
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2014, 52 (09): : 1093 - 1094
  • [2] Pellagra, azathioprine and inflammatory bowel disease
    Jarrett, P
    Duffill, M
    Oakley, A
    Smith, A
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1997, 22 (01) : 44 - 45
  • [3] Is azathioprine safe as long-term treatment in paediatric patients with inflammatory bowel disease?
    Martinez Ibeas, M. A.
    Bacelo Ruano, I.
    Rodriguez Manchon, S.
    Velasco Rodriguez-Belvis, M.
    Viada Bris, J. F.
    Dominguez Ortega, G.
    Munoz Codoceo, R. A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S573 - S573
  • [4] Immunosuppressive drugs in inflammatory bowel disease: azathioprine
    Atreya, I.
    Neurath, M. F.
    [J]. IBD 2007 - ACHIEVEMENTS IN RESEARCH AND CLINICAL PRACTICE, 2008, 159 : 153 - 161
  • [5] Azathioprine: State of the art in inflammatory bowel disease
    Sandborn, WJ
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1998, 33 : 92 - 99
  • [6] Azathioprine dose escalation in inflammatory bowel disease
    Rayner, CK
    Hart, AL
    Hayward, CMM
    Emmanuel, AV
    Kamm, MA
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (01) : 65 - 71
  • [7] TPMT in the treatment of inflammatory bowel disease with azathioprine
    Qasim, A
    Seery, J
    Buckley, M
    Morain, CO
    [J]. GUT, 2003, 52 (05) : 767 - 767
  • [8] Azathioprine hypersensitivity mimicking underlying inflammatory bowel disease
    Corbett, M
    Schlup, M
    [J]. INTERNAL MEDICINE JOURNAL, 2001, 31 (06) : 366 - 367
  • [9] AZATHIOPRINE PHARMACOKINETICS IN EARLY ONSET INFLAMMATORY BOWEL DISEASE
    Stocco, Gabriele
    Martelossi, Stefano
    De Iudicibus, Sara
    Favretto, Diego
    Cuzzoni, Eva
    Franca, Raffaella
    Decorti, Giuliana
    Ventura, Alessandro
    [J]. DIGESTIVE AND LIVER DISEASE, 2014, 46 : E77 - E78
  • [10] Azathioprine active metabolite concentrations in inflammatory bowel disease
    Wright, S
    Sanders, DS
    Lennard, L
    Lobo, AJ
    [J]. GUT, 2003, 52 : A13 - A13
12345